QUOTE AND NEWS
SeekingAlpha  Oct 17  Comment 
By Spencer Osborne: Sales of the Arena Pharmaceuticals (NASDAQ:ARNA) anti-obesity pill Belviq seem to be seeing some impacts of seasonality with ups and downs as the Fall weeks progress. This week sales declined 1.8% according to industry tracker...
SeekingAlpha  Oct 10  Comment 
By Spencer Osborne: Sales of Belviq, the anti-obesity drug from Arena Pharmaceuticals (NASDAQ:ARNA) were up this week and now pacing slightly ahead of the "guidance" pace I outlined many months ago. When you look at my weekly chart you will note...
StreetInsider.com  Oct 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Arena+Pharma+%28ARNA%29%2C+Eisai+Report+Publication+of+Encouraging+data+from+Belviq+BLOSSOM+Trial/9902756.html for the full story.
SeekingAlpha  Oct 3  Comment 
By Spencer Osborne: Sales of Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE:IMS). Script sales came in at about 11,800, and were down 0.5%. The numbers...
SeekingAlpha  Oct 3  Comment 
By Emerging Equities: Arena Pharmaceuticals Inc. (NASDAQ:ARNA) is known primarily for its anti-obesity drug Belviq®. This is not surprising as it is the company's only approved drug at the moment. Also, it was one of the three anti-obesity drugs...
SeekingAlpha  Sep 26  Comment 
By SA Transcripts: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) NewsMakers in the Biotech Industry Conference September 26, 2014 11:30 A.M. ET Executives Unidentified Participant Craig M. Audet - SVP of Operations and Head of Global...
SeekingAlpha  Sep 26  Comment 
By Spencer Osborne: Script sales of the anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) saw a nice week over week gain on the heels of a more robust advertising campaign. According to IMS Health, script sales this week were about...
SeekingAlpha  Sep 22  Comment 
By Spencer Osborne: While there have been rumblings in the past about the advertising campaign with Arena Pharmaceuticals' (NASDAQ:ARNA) anti-obesity drug Belviq, the most recent two weeks have demonstrated a distinct shift in the television...
SeekingAlpha  Sep 21  Comment 
By Spencer Osborne: Arena Pharmaceuticals' (NASDAQ:ARNA) anti-obesity pill Belviq saw a full recovery from a holiday dip in sales last week with a 15% gain this week. Sales in the most recent week demonstrated a full recovery plus a modest...
SeekingAlpha  Sep 19  Comment 
By Spencer Osborne: Arena Pharmaceuticals (NASDAQ:ARNA) seems to always have something compelling happening. Last week I published an article that assessed the impact of Belviq and phentermine from the perspective of the study design by a doctor...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki